Recruiting

Laguna Thrombectomy

Sponsor:

Innova Vascular, Inc.

Code:

NCT06041594

Conditions

Pulmonary Embolism

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Laguna Thrombectomy System

Study Details

Brief summary:

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

Conditions

Pulmonary Embolism

Study ID

NCT06041594

Start date

Aug 19, 2024

Status verified date

Jul, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Aug, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. ≥ 18 years of age; < 85 years old
2. RV/LV ratio > 0.9 as determined by CTA
3. Systolic blood pressure > 90 mmHg
4. Heart rate ≤ 120
5. Patient is deemed eligible for procedure by the interventional investigator
6. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
7. PE Symptom duration ≤ 14 days

Exclusion Criteria:

1. Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments
2. Life expectancy of < 90 days in the opinion of investigator at the time of enrollment
3. Subject pregnant or breast feeding
4. Current participation in another drug or medical device treatment study
5. In active chemotherapy or radiation treatment for a malignancy during the course of the study
6. Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
7. Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
8. History of prior PE within the past 90 days
9. FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90%
10. Hematocrit: < 28%
11. Platelets: < 100,000/microliter
12. Serum Creatinine: > 2 mg/dL
13. International Normalized Ratio (INR): > 3
14. Major Trauma Injury Severity Score (ISS): > 15
15. Cardiovascular or pulmonary surgery within the last 7 days
16. Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
17. History of known severe or chronic pulmonary arterial hypertension
18. History or chronic left heart disease with left ventricular ejection fraction < 30%
19. History of underlying lung disease that is oxygen dependent
20. History of chest irradiation
21. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
22. Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
23. Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
24. Known presence of clot in transit within right atrium or ventricle

Study Design

Enrollment

107 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Laguna Thrombectomy System

Interventions

Laguna Thrombectomy System

Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism

Primary outcome measure

  • A composite of the following major adverse events occurring within 48 (± 8) hours post-procedure: [ Time Frame: within 48 (± 8) hours post-procedure ]
  • Reduction in RV/LV ratio from baseline to 48 (± 8) hours (or at discharge, whichever occurs first) as assessed by Computed Tomography Angiography (CTA) [ Time Frame: from baseline to 48 (± 8) hours (or at discharge, whichever occurs first) ]

Central Contacts and Locations

Central contacts

Sanjay Shrivastava, Ph.D.

949-295-6040ss@innovavascular.com

Locations

Grandview Medical Center

Recruiting

Birmingham, Alabama, United States, 35243

University of Arizona

Recruiting

Tucson, Arizona, United States, 85724

University of California Irvine

Recruiting

Irvine, California, United States, 92697

Memorial Care Long Beach Medical Center

Recruiting

Long Beach, California, United States, 90806

Mission Hospital Regional Medical Center

Recruiting

Mission Viejo, California, United States, 92691

St. Joseph Hospital of Orange

Recruiting

Orange, California, United States, 92868

George Washington University

Recruiting

Washington D.C., District of Columbia, United States, 20037

Manatee Memorial Hospital

Recruiting

Bradenton, Florida, United States, 34209

Physicians Regional Medical Center

Recruiting

Naples, Florida, United States, 34119

University of North Carolina at Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 27599

OhioHealth Research Institute

Recruiting

Columbus, Ohio, United States, 43214

Turkey Creek Medical Center

Recruiting

Knoxville, Tennessee, United States, 37934

University of Texas Southwestern

Recruiting

Dallas, Texas, United States, 75390

More Information

Sponsor

Innova Vascular, Inc.

Last update posted

Jul 17, 2026

Last verified

Jul, 2026

Keywords

  • Laguna Thrombectomy System
  • Pulmonary Embolism

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Innova Vascular, Inc. on 2026-07-17.